ARCHIVES

FDA Promises No More IND Disruptions Without “Very Valid Reasons,” Nears Agreement With NCI

This article is from The Cancer Letter archive.

Vol. 03 No. 15 | April 15, 1977

Download PDF Visit The Full Archive

Related Articles

FDA Approves Afinitor-Aromasin Regimen For Advanced HER2-Negative Breast Cancer

July 27, 2012

DCPC BSC Committee Endorses Three Research Concepts

April 17, 1987

Clinical Center’s Cancer Nursing Recruitment Improved

January 10, 1986

In Brief: NIH Reviewers, Advisors To Get Increase In Honoraria; Price Leaving NCI for Maryland

March 14, 1980

National Cancer Policy Board calls for public-private partnership for R&D in pediatric cancer drugs.

April 22, 2005

Risk of Relapse Continues After Five Years of Therapy

August 29, 2008